WV Supreme Court Invokes Learned Intermediary Doctrine

Last year, pharmaceutical companies reportedly spent $4.5 billion on direct advertising to consumers, or about 400 times more than they spent 20 years ago. Drug company spending on advertising to consumers is increasing twice as fast as spending on promotions to physicians or on the research and development of new drugs. Given this exponential growth in direct-to-consumer advertising, it is hardly surprising that prescription drug makers' traditional immunity from consumer 'failure-to-warn' claims has increasingly come under assault. Although many courts have resisted calls from the plaintiffs' bar to allow such claims, recent decisions have created uncertainty about the future.